Aptevo Therapeutics Inc. — Investor Relations & Filings
Filings indexed
684
across all filing types
Latest filing
2026-05-27
Regulatory Filings
Country
US
United States of America
Listing
US
APVO
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company specializes in creating bispecific and trispecific antibody-based therapeutics designed to harness a patient's immune system to fight malignancies. Its pipeline includes multiple candidates targeting both hematologic cancers and solid tumors. The lead candidate, Mipletamig, is a CD3 T-cell engager targeting the CD123 tumor antigen for the treatment of Acute Myeloid Leukemia (AML). Other programs in development target various tumor antigens, including PSMA for prostate cancer and Nectin-4 for solid tumors, utilizing mechanisms like T-cell engagement and co-stimulation to enhance anti-tumor activity.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-27 | English | |
| 8-K - Aptevo Therapeutics Inc. (0001671584) (Filer) | 2026-05-06 | English | |
| Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment | 2026-03-27 | English | |
| 8-K - APTEVO THERAPEUTICS INC. (0001671584) (Filer) | 2026-02-19 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English |
Browse filings by year
11 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
12 filings
| |||||
| 47843726 | 8-K | 2026-05-27 | English | ||
| 42001589 | 8-K - Aptevo Therapeutics Inc. (0001671584) (Filer) | 2026-05-06 | English | ||
| 33062838 | Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment | 2026-03-27 | English | ||
| 32896295 | 8-K - APTEVO THERAPEUTICS INC. (0001671584) (Filer) | 2026-02-19 | English | ||
| 31224528 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31224515 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31224508 | 8-K Filing | 2026-02-03 | English | ||
| 31224455 | 424B4 Filing | 2026-01-30 | English | ||
| 31224522 | S-1 Filing | 2026-01-28 | English | ||
| 31224517 | DEF 14A Filing | 2026-01-26 | English | ||
| 12947011 | PRE 14A | 2026-01-16 | English | ||
| 12947014 | 8-K | 2026-01-09 | English | ||
|
2025
3 filings
| |||||
| 12947015 | 8-K | 2025-12-29 | English | ||
| 12947016 | 8-K | 2025-12-09 | English | ||
| 12947017 | Regulatory Filings 2025 | 2025-11-26 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Annovis Bio, Inc.
A clinical-stage drug platform company developing therapies…
|
ANVS | US | Professional, scientific and te… |
|
AnorMED Inc.
Developed small molecule therapeutics for serious diseases,…
|
— | CA | Professional, scientific and te… |
|
ANTEOTECH LTD
Develops nanoglue technology for life sciences and lithium-…
|
ADO | AU | Professional, scientific and te… |
|
Anthem Biosciences Limited
Integrated CRAMS organization for drug discovery, developme…
|
ANTHEM | IN | Professional, scientific and te… |
|
APPLIED DNA SCIENCES INC
Develops and manufactures DNA-based technologies for geneti…
|
APDN | US | Professional, scientific and te… |
|
Aprea Therapeutics, Inc.
Clinical-stage biopharma developing cancer therapeutics via…
|
APRE | US | Professional, scientific and te… |
|
AprilBio Co.,Ltd.
Develops long-acting biologic drugs for autoimmune diseases…
|
397030 | KR | Professional, scientific and te… |
|
Aptahem AB
A clinical-stage biotech developing aptamer-based drugs for…
|
APTA | SE | Professional, scientific and te… |
|
APTAMER GROUP PLC
Develops custom affinity binders for research, diagnostics,…
|
APTA | GB | Professional, scientific and te… |
|
Aptose Biosciences Inc.
Clinical-stage company developing targeted precision medici…
|
APS | CA | Professional, scientific and te… |
Aptevo Therapeutics Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35422/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35422 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35422 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35422 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35422}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Aptevo Therapeutics Inc. (id: 35422)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.